Selinexor Patent Expiration

Selinexor is Used for treating relapsed or refractory Diffuse Large B-Cell Lymphoma (DLBCL) and Multiple Myeloma in adults. It was first introduced by Karyopharm Therapeutics Inc in its drug Xpovio on Jul 3, 2019.


Selinexor Patents

Given below is the list of patents protecting Selinexor, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Xpovio US10519139 Polymorphs of Selinexor Aug 14, 2035 Karyopharm Theraps
Xpovio US10544108 Hydrazide containing nuclear transport modulators and uses thereof Jul 26, 2032 Karyopharm Theraps
Xpovio US11034660 Hydrazide containing nuclear transport modulators and uses thereof Jul 26, 2032 Karyopharm Theraps
Xpovio US11746102 Polymorphs of selinexor Aug 14, 2035 Karyopharm Theraps
Xpovio US11753401 Polymorphs of Selinexor Aug 14, 2035 Karyopharm Theraps
Xpovio US11787771 Hydrazide containing nuclear transport modulators and uses thereof Jul 26, 2032 Karyopharm Theraps
Xpovio US11807629 Polymorphs of Selinexor Aug 14, 2035 Karyopharm Theraps
Xpovio US8999996 Hydrazide containing nuclear transport modulators and uses thereof Jul 03, 2033 Karyopharm Theraps
Xpovio US9079865 Hydrazide containing nuclear transport modulators and uses thereof Jul 26, 2032 Karyopharm Theraps
Xpovio US9714226 Hydrazide containing nuclear transport modulators and uses thereof Jul 26, 2032 Karyopharm Theraps


A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Selinexor's patents.

Given below is the list recent legal activities going on the following patents of Selinexor.

Event Date Patent/Publication
Patent litigations
Patent eGrant Notification 07 Nov, 2023 US11807629
Mail Patent eGrant Notification 07 Nov, 2023 US11807629
Recordation of Patent Grant Mailed 07 Nov, 2023 US11807629
Recordation of Patent eGrant 07 Nov, 2023 US11807629
Email Notification 07 Nov, 2023 US11807629
Patent Issue Date Used in PTA Calculation 07 Nov, 2023 US11807629
Email Notification 19 Oct, 2023 US11807629
Issue Notification Mailed 18 Oct, 2023 US11807629
Email Notification 17 Oct, 2023 US11787771
Patent Issue Date Used in PTA Calculation 17 Oct, 2023 US11787771



Coming Soon

Patent Strength Analyzer

Will this be useful for you?

YesNo

Thank you for your response 🥳